Summit Therapeutics Inc.
SMMT
$26.20
$0.190.73%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Net Income | -799.19% | -2.79% | -8.80% | 6.84% | -38.90% |
Total Depreciation and Amortization | 48.00% | 13.64% | 10.00% | 0.00% | -25.93% |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | 5,939.99% | -40.08% | -22.27% | -30.34% | 167.35% |
Change in Net Operating Assets | 446.02% | -801.75% | -107.65% | 199.07% | -28.61% |
Cash from Operations | -9.12% | -25.67% | -60.65% | 8.20% | -9.52% |
Capital Expenditure | 100.00% | -2,914.29% | 75.86% | 7.94% | -1,475.00% |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | -6.06% | 92.26% | 176.91% | 45.73% | -1,106.37% |
Cash from Investing | -5.81% | 91.79% | 176.86% | 45.71% | -1,106.89% |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -- | -- | 67.55% | -- | -- |
Issuance of Common Stock | -71.06% | 764.53% | -99.68% | 39.67% | 41,180.82% |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | -- | -- | -- | -- |
Cash from Financing | -71.06% | 132.51% | -111.57% | 1.96% | 41,180.82% |
Foreign Exchange rate Adjustments | 60.53% | 135.19% | -194.74% | 850.00% | 133.33% |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | -19.04% | 861.83% | -83.03% | 298.87% | -234.80% |